表紙
市場調査レポート

脳内出血:世界の治験レビュー

Intracerebral Hemorrhage Global Clinical Trials Review, H1, 2016

発行 GlobalData 商品コード 308257
出版日 ページ情報 英文 89 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
脳内出血:世界の治験レビュー Intracerebral Hemorrhage Global Clinical Trials Review, H1, 2016
出版日: 2016年06月30日 ページ情報: 英文 89 Pages
概要

当レポートでは、脳内出血に関する臨床研究の最新動向について分析し、疾患治療法の概要や、治験における主要国、G7諸国およびE7(新興7カ国)における治験数および被験者採用の状況、地域フェーズ(相)段階別の進行状況、有望なスポンサー、各企業研究機関での研究の進行状況、有望な薬剤の比較といった情報をまとめてお届けします。

目次

イントロダクション

  • 脳内出血
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東およびアフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:中枢神経系の治験件数に対する脳内出血の治験件数比率

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7(新興7ヶ国)諸国での治験件数:中枢神経系の治験件数に対する脳内出血の治験件数比率

E7(新興7ヶ国)諸国での治験件数:フェーズ(相)別

E7(新興7ヶ国)諸国での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

エンドポイント達成状況別の治験件数

未達成の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • Novo A/S
    • The Medicines Company
    • Pfizer Inc.
    • Octapharma AG
    • GlaxoSmithKline plc
    • AstraZeneca PLC
  • 代表的な研究機関・病院の治験の概要
    • Johns Hopkins University
    • Beth Israel Deaconess Medical Center
    • University of Minnesota
    • Sunnybrook Health Sciences Centre
    • Thomas Jefferson University
    • University of California, Los Angeles
    • University of Erlangen-Nurnberg
    • The George Institute for Global Health
    • University of Oulu
    • University of Heidelberg

5つの代表的な治験のプロファイル

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3544CTIDB

GlobalData's clinical trial report, "Intracerebral Hemorrhage Global Clinical Trials Review, H1, 2016" provides an overview of Intracerebral Hemorrhage clinical trials scenario. This report provides top line data relating to the clinical trials on Intracerebral Hemorrhage. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Intracerebral Hemorrhage to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Intracerebral Hemorrhage to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Intracerebral Hemorrhage Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials by Region, 2016*
  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Central and South America, Top Countries, 2016*
  • Proportion of Intracerebral Hemorrhage to Central Nervous System Clinical Trials, G7 Countries (%), 2016*
  • Intracerebral Hemorrhage Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Intracerebral Hemorrhage Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Intracerebral Hemorrhage to Central Nervous System Clinical Trials, E7 Countries (%), 2016*
  • Intracerebral Hemorrhage Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Intracerebral Hemorrhage Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Intracerebral Hemorrhage Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Proportion of Intracerebral Hemorrhage to Central Nervous System Clinical Trials, G7 Countries (%), 2016*
  • Intracerebral Hemorrhage Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Intracerebral Hemorrhage Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Intracerebral Hemorrhage to Central Nervous System Clinical Trials, E7 Countries (%), 2016*
  • Intracerebral Hemorrhage Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Intracerebral Hemorrhage Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Intracerebral Hemorrhage Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Intracerebral Hemorrhage Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Intracerebral Hemorrhage Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top